Medivation rejects Sanofi's $9.3 billion bidStaff writer ▼ | April 29, 2016
Medivation said it rejected Sanofi's $9.3 billion takeover offer, claiming that the French drugmaker's proposal "undervalues" the cancer-treatment company.
Acquisition Sanofi "undervalues" its takeover target
Medivation said its board had unanimously rejected the Sanofi's offer and that the proposal would deny its shareholders of the value in its late-stage pipeline, as well as its flagship oncology drug, Xtandi.
Sanofi responded Friday by saying it remained "committed" to the transaction and looked forward to "engaging directly with Medivation shareholders."
Sanofi's offer of $52.50 a share was a 50% premium on Medivation's average share price for the two months before takeover speculation emerged, though lower than Medivation's current share price, which was buoyed by takeover speculation. ■